Natural killer cell engagers: From bi‐specific to tri‐specific and tetra‐specific engagers for enhanced cancer immunotherapy
Clinical and Translational Medicine2024Vol. 14(11), pp. e70046–e70046
Citations Over TimeTop 10% of 2024 papers
Abstract
Current clinical trials demonstrate the safety and efficacy of various NKCEs across different cancer types. Future research directions: Optimising NKCE designs and exploring combination therapies are essential for overcoming challenges in cancer treatment.
Related Papers
- → B7-H3/CD276: An Emerging Cancer Immunotherapy(2021)282 cited
- → Cancer Immunotherapy and Application of Nanoparticles in Cancers Immunotherapy as the Delivery of Immunotherapeutic Agents and as the Immunomodulators(2020)80 cited
- → CAR-T Immunotherapy to Beat Solid Tumors: From Challenges to Improvements(2022)2 cited
- → The present situation and prospect of CAR-T cellular immunotherapy(2020)
- → Current status and problems of chimeric antigen receptor T cell immunotherapy in treatment of hematological malignancies(2020)